Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902664-25-003291
Filing Date
2025-07-31
Accepted
2025-07-31 16:36:37
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 12260
  Complete submission text file 0000902664-25-003291.txt   13982
Mailing Address 1 ROCKEFELLER PLAZA, SUITE 1205 NEW YORK NY 10020
Business Address 1 ROCKEFELLER PLAZA, SUITE 1205 NEW YORK NY 10020 212-608-3300
Empery Asset Management, LP (Filed by) CIK: 0001469336 (see all company filings)

EIN.: 262107121 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Subject) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92757 | Film No.: 251172223
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)